300 related articles for article (PubMed ID: 24117733)
1. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
Luerman GC; Nguyen C; Samaroo H; Loos P; Xi H; Hurtado-Lorenzo A; Needle E; Stephen Noell G; Galatsis P; Dunlop J; Geoghegan KF; Hirst WD
J Neurochem; 2014 Feb; 128(4):561-76. PubMed ID: 24117733
[TBL] [Abstract][Full Text] [Related]
2. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
[TBL] [Abstract][Full Text] [Related]
3. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
Gillardon F
J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
[TBL] [Abstract][Full Text] [Related]
4. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
Gillardon F; Schmid R; Draheim H
Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and Tropomyosin 4.
Häbig K; Gellhaar S; Heim B; Djuric V; Giesert F; Wurst W; Walter C; Hentrich T; Riess O; Bonin M
Biochim Biophys Acta; 2013 Dec; 1832(12):2352-67. PubMed ID: 24075941
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
[TBL] [Abstract][Full Text] [Related]
9. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
[TBL] [Abstract][Full Text] [Related]
10. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β.
Kawakami F; Shimada N; Ohta E; Kagiya G; Kawashima R; Maekawa T; Maruyama H; Ichikawa T
FEBS J; 2014 Jan; 281(1):3-13. PubMed ID: 24165324
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor α-mediated neurotoxicity.
Ho DH; Seol W; Eun JH; Son IH
Biochem Biophys Res Commun; 2017 Jan; 482(4):1088-1094. PubMed ID: 27914807
[TBL] [Abstract][Full Text] [Related]
12. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
13. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
Plowey ED; Cherra SJ; Liu YJ; Chu CT
J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054
[TBL] [Abstract][Full Text] [Related]
14. Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.
Ho DH; Kim H; Kim J; Sim H; Ahn H; Kim J; Seo H; Chung KC; Park BJ; Son I; Seol W
Mol Brain; 2015 Sep; 8():54. PubMed ID: 26384650
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity.
Zach S; Felk S; Gillardon F
PLoS One; 2010 Oct; 5(10):e13191. PubMed ID: 20949042
[TBL] [Abstract][Full Text] [Related]
16. Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration.
Caesar M; Zach S; Carlson CB; Brockmann K; Gasser T; Gillardon F
Neurobiol Dis; 2013 Jun; 54():280-8. PubMed ID: 23318930
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.
Civiero L; Cirnaru MD; Beilina A; Rodella U; Russo I; Belluzzi E; Lobbestael E; Reyniers L; Hondhamuni G; Lewis PA; Van den Haute C; Baekelandt V; Bandopadhyay R; Bubacco L; Piccoli G; Cookson MR; Taymans JM; Greggio E
J Neurochem; 2015 Dec; 135(6):1242-56. PubMed ID: 26375402
[TBL] [Abstract][Full Text] [Related]
18. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
[TBL] [Abstract][Full Text] [Related]
19. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
[TBL] [Abstract][Full Text] [Related]
20. A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in
Lin CH; Lin HY; Fang JM; Chen CC
Aging (Albany NY); 2020 Nov; 12(24):25581-25598. PubMed ID: 33231564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]